Rezolute, Inc. Price & Performance (RZLT)

Rezolute has secured about $90 million through a public offering of common stock and pre-funded warrants, drawing major investment from firms like Blackstone and Federated Hermes Kaufmann. The influx will fund late-stage drug development, notably its therapy for congenital hyperinsulinism, and extends operational runway through early 2026.123

Rezolute’s stock jumped nearly 28% after announcing its $90 million capital raise and positive late-stage trial news. The uptick signals revived investor optimism in biotech milestones, with the company’s healthy cash position and new institutional commitments potentially setting the stage for further growth.145

Rezolute’s appointment of biopharma veteran Erik Harris to its board, alongside the substantial capital raise, is being interpreted as a double boost for the company. While financials show ongoing losses, robust liquidity and expert leadership are fueling speculation about a potential turnaround in its rare disease pipeline.456